Publications of Udo Reichl
All genres
Talk (263)
401.
Talk
Scale-Down of an Ortbital Shaken Bioreactor: High Cell Density Cultivation in Perfusion Mode and Virus production. Single-Use Technologies V: Building the Future, Marseille, France (2022)
402.
Talk
Integrated cell-culture based MVA virus production process with perfusion mode for vaccines or gene therapy. Value through intensified bioprocessing II, Oxford, United Kingdom (2022)
403.
Talk
Integrated cell-culture based MVA virus production process with perfusion mode for vaccines or gene therapy. 27th ESACT Meeting, Lisbon (Portugal) (2022)
404.
Talk
Production of influenza A virus defective interfering particles in a high cell density perfusion cultivation with continuous virus harvesting. Vaccine Technology VIII, Sitges (Spain) (2022)
405.
Talk
Influenza A Virus-Derived Defective Interfering Particles for Antiviral Treatment. 27th ESACT Meeting, Lisbon (Portugal) (2022)
406.
Talk
Towards full control over protein glycosylation: In-vitro glycoengineering of Influenza A virus Hemagglutinin and SARS-CoV-2 spike protein. 32nd Joint Glycobiology Meeting, Utrecht (The Netherlands) (2022)
407.
Talk
Biological methanation using a tubular foam bioreactor. Smart Process Systems Engineering 2022 Towards Sustainable & Circular Production Processes (SmartProSys 2022), Magdeburg, Germany (2022)
408.
Talk
Adaptation of a methanogenic community to demand-oriented biological methanation. 4th International Metaproteomics Symposium, Luxembourg, Luxembourg (2022)
409.
Talk
Influenza A Virus Defective Interfering Particles for Antiviral Treatment of the Influenza Disease and COVID-19. 31st Annual Meeting of the Society for Virology, online (2022)
410.
Talk
Long-Term Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing Dynamic Competition to Select Antiviral Candidates. Vaccine Technology VIII, Sitges (Spain) (2022)
411.
Talk
Semi-Continuous propagation of Influenza A virus and its defective interfering particles: Analyzing the dynamic competition to select antiviral candidates. 27th ESACT Meeting, Lisbon (Portugal) (2022)
412.
Talk
Modeling the intracellular replication of a new type of defective interfering particle of influenza virus with genomic nucleotide substitutions. 12th European Conference on Mathematical and Theoretical Biology, Heidelberg (Germany) (2022)
413.
Talk
Automated single-cell cloning in chemically defined medium for new suspension MDCK cell lines and scale-down of influenza A virus production into ambr®15 microbioreactors. Vaccine Technology VIII, Sitges (Spain) (2022)
414.
Talk
Combined metagenomics and metaproteomics of a two-stage biogas plant questions the benefit of the hydrolysis fermenter for process performance. 4th International Metaproteomics Symposium, Luxembourg, 2021, Luxembourg, Luxembourg (2021)
415.
Talk
Adaptation of a microbial community to demand-oriented biological methanation. V. International Conference on Monitoring & Process Control of Anaerobic Digestion Processes, virtual (2021)
416.
Talk
Cell Culture-based Virus Production Revisited: Applications, Needs, Chances and Challenges. Jahrestagung der Max-Planck-Gesellschaft, online (2021)
417.
Talk
Multiscale model of influenza A virus and defective interfering particle co-infection in animal cell culture. 5th Workshop on Virus Dynamics, virtual (2021)
418.
Talk
Evolution and selection of influenza a virus defective interfering particles in a semi-continuous production system for the use as antiviral. The seventh ESWI Influenza Conference, Virtual Meeting (2020)
419.
Talk
Cell Culture-based Viral Vaccines: Process Intensification and Monitoring. Plenarsitzung der Sächischen Akademie der Wissenschaften zu Leipzig, Leipzig, Germany (2020)
420.
Talk
Multiscale model of DIP replication and its effects on influenza A virus infection in animal cell culture. Society for Mathematical Biology 2020 Annual Meeting, Virtual Meeting (2020)